Category Medicine and Healthcare
Press Release
Moderna Reports Second Quarter 2024 Financial Results and Provides Business Updates
Reports second quarter revenues of $241 million, GAAP net loss of $1.3 billion and GAAP EPS of $(3.33) Updates 2024 financial framework and revises expectations for product sales to $3.0 to $3.5 billion Received U.S. FDA approval for RSV vaccine, mRESVIA, and began shipping in July; received EMA positive opinion in June Announced positive Phase 3 data for combination vaccine against influenza and COVID-19 Announced positive Phase 3 data for next-generation COVID-19 vaccine Read More
Press Release
Issuance of New European Patent Bolsters IP Protection for Jaguar Health in the Treatment of Congenital Diarrheal Disorders (CDDs)
New patent issued for core rare disease target indication for crofelemer Jaguar has approximately 200 patents issued and pending Jaguar is supporting investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of short bowel syndrome (SBS) and microvillus inclusion disease (MVID), an ultrarare CDD, in the US, EU, and Middle East/North Africa regions, with proof-of-concept results expected before the end of 2024 and throughout 2025 Read More
Press Release
Interactive Strength Inc. (Nasdaq: TRNR) Secures Exclusive Distribution for CLMBR in Germany and Receives Six-Figure Initial Order
German Distributor placed six-figure initial order that is expected to ship in the third quarter of 2024 Germany is the largest fitness market after the United States Germany's largest fitness company, RSG Group, owns Gold's Gym and McFIT among other brands Read More
Press Release
NLS Pharmaceutics and Kadimastem Announce Binding Term Sheet to Merge
The proposed transaction will create a Nasdaq-traded, biotechnology company with product candidates in advanced stages of clinical development and focused on advancing Kadimastem's allogeneic cell therapy platform Each of Kadimastem and NLS Pharmaceutics has received commitments of support for the transaction from shareholders representing more than 40% of their respective outstanding shares Read More
Press Release
Skyscape’s Buzz Earns Top Customer Satisfaction Awards While Helping Home Health Care Providers Remain Profitable
Buzz was recognized in multiple categories as part of the Summer 2024 G2 Grid Report, an analysis based on user product reviews. In the G2 report, Buzz achieved a Net Promoter Score (NPS) of 95 while receiving badges for Best HIPAA Compliant Messaging, Best Communication & Collaboration Platform, Best Support, Easiest to Do Business With, and Momentum Leader. Read More
Press Release
Interactive Strength Inc.’s (Nasdaq: TRNR) CLMBR Earns Approved Vendor Partner status from Crunch Fitness and is Invited to the 2024 Crunch Franchise Convention
CLMBR is now an Approved Vendor Partner for Crunch Fitness franchisees, following a successful pilot at Crunch West Hollywood earlier this year CLMBR is exhibiting at the Annual Crunch Franchise Convention, from July 28 to August 1 in Phoenix, AZ There are more than 460 locations and 2.5 million members in the Crunch Fitness system Read More
Press Release
Ainos Enrolls First Subject for Clinical Study of VELDONA-Based Animal FCGS Drug
The clinical study of new potential VELDONA-based animal drug is poised to expand VELDONA's market. This clinical trial aims to complete the enrollment of 30 subjects by the end-2024 with the trial report to be finalized in Q1 2025. Read More
Press Release
Jaguar Health Reports Phase 3 OnTarget Trial Results for its Cancer Supportive Care Drug Crofelemer
Initial results of unprecedented trial including 10 different tumor types indicate that OnTarget did not meet its primary endpoint across all tumor types. Trial did reveal clinically relevant signals for crofelemer in prespecified subgroups of patients with breast and respiratory cancer, including lung cancer. Jaguar to host investor webcast Tuesday, July 23rd at 8:30 AM Eastern to provide updates on company's cancer supportive care portfolio, including participation from Jaguar scientific team, patient advocates, and leading oncology experts on cancer therapy-related diarrhea (CTD) and oral mucositis; Click here to register for webcast. Read More
Press Release
David Rubenstein Joins Moderna's Board of Directors
Co-Founder and Co-Chairman of The Carlyle Group brings multi-industry investor experience and global policy expertise, replacing retiring director Stephen Berenson Co-founder and director Robert Langer also to retire from the Moderna Board; recruitment efforts ongoing for his replacement Read More
Press Release
BMCS and Commodity Vault Enter Into The Real-World Assets Tokenization Ecosystem
BioTech Medics, Inc. (OTC PINK:BMCS) and its subsidiary Commodity Vault are pleased to announce that the firms have created the architecture for our RWA Tokenization Trading Platform that includes, tokens, various commodities, verified blockchains, white papers, apps, wallets, websites, stocks and strategic partnerships all of these components, and more encompass our ecosystem Read More
Press Release
Jaguar Health to Report Phase 3 OnTarget Trial Results for Its Cancer Supportive Care Drug Crofelemer on July 23rd and Hold Investor Webcast that Morning
Webcast on Tuesday, July 23rd at 8:30 AM Eastern will include updates on Jaguar's cancer supportive care portfolio, including participation from Jaguar scientific team, patient advocates, and leading oncology experts on cancer therapy-related diarrhea (CTD) and oral mucositis; Click here to register for webcast Jaguar expands Make Cancer Less Shitty (MCLS) patient advocacy program to incorporate select group of MCLS Ambassadors - cancer survivors who understand the realities of cancer and are no longer willing to accept debilitating side effects of cancer treatments as an acceptable trade-off for survival Cancer patients with diarrhea are 40% more likely to discontinue their therapy; oral mucositis affects up to 40% of patients undergoing chemotherapy and approximately 90% of those receiving chemoradiation for head and neck cancers, with more than one-third of patients discontinuing cancer treatment because of the condition Read More
Press Release
